Compare BRBS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBS | ARMP |
|---|---|---|
| Founded | 1893 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.8M | 295.5M |
| IPO Year | 2015 | 1996 |
| Metric | BRBS | ARMP |
|---|---|---|
| Price | $3.58 | $5.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 419.3K | 169.4K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 24.78% | N/A |
| EPS Growth | ★ 135.48 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $111,284,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $359.00 | ★ N/A |
| Revenue Growth | ★ 123.99 | N/A |
| 52 Week Low | $3.23 | $2.14 |
| 52 Week High | $4.79 | $14.98 |
| Indicator | BRBS | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 65.21 | 34.26 |
| Support Level | $3.24 | $5.14 |
| Resistance Level | $3.71 | $7.93 |
| Average True Range (ATR) | 0.07 | 0.72 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 79.27 | 2.40 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance, and others. It generates the majority of its revenue from commercial banking.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.